Quantum Cyber N.V. Adjustments For Depreciation And Amortisation Expense
Quantum Cyber N.V. (QUCY) reported Adjustments For Depreciation And Amortisation Expense of $499.93 thousand for the 6-month period ending 2025-06-30, per its 6-K filed 2025-09-26.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense · last filed 2025-09-26
- Quantum Cyber N.V. adjustments for depreciation and amortisation expense for the quarter ending 2023-12-31 was $204.47K, a 16.38% decline year-over-year.
- Quantum Cyber N.V. adjustments for depreciation and amortisation expense for the quarter ending 2023-09-30 was $203.57K, a 179.22% increase year-over-year.
- Quantum Cyber N.V. adjustments for depreciation and amortisation expense for the quarter ending 2023-06-30 was $171.02K, a 521.63% increase year-over-year.
- Quantum Cyber N.V. adjustments for depreciation and amortisation expense for the quarter ending 2023-03-31 was $287.35K, a 724.35% increase year-over-year.
| Period end | Adjustments For Depreciation And Amortisation Expense 3 month | Adjustments For Depreciation And Amortisation Expense 6 month | Adjustments For Depreciation And Amortisation Expense 9 month | Adjustments For Depreciation And Amortisation Expense 12 month |
|---|---|---|---|---|
| 2025-06-30 | $499.93K 6-K · filed 2025-09-26 | |||
| 2024-12-31 | $1.02M 20-F · filed 2025-03-31 | |||
| 2024-06-30 | $496.95K 6-K · filed 2025-09-26 | |||
| 2023-12-31 | $204.47K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-31 | $408.04K derived: sum of 2 quarters · filed 2025-03-31 | $579.06K derived: sum of 3 quarters · filed 2025-03-31 | $866.41K 20-F · filed 2025-03-31 |
| 2023-09-30 | $203.57K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-16 | $374.59K derived: sum of 2 quarters · filed 2024-10-18 | $661.94K 6-K · filed 2023-11-16 | $906.46K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $171.02K derived: 6-K 6 month − 6-K 3 month · filed 2024-10-18 | $458.37K 6-K · filed 2024-10-18 | $702.89K derived: sum of 3 quarters · filed 2025-03-31 | $775.80K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $287.35K 6-K · filed 2023-05-16 | $531.87K derived: sum of 2 quarters · filed 2025-03-31 | $604.78K derived: sum of 3 quarters · filed 2025-03-31 | $632.29K derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $244.52K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-31 | $317.43K derived: sum of 2 quarters · filed 2025-03-31 | $344.94K derived: sum of 3 quarters · filed 2025-03-31 | $379.80K 20-F · filed 2025-03-31 |
| 2022-09-30 | $72.91K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-16 | $100.42K derived: sum of 2 quarters · filed 2023-11-16 | $135.28K 6-K · filed 2023-11-16 | |
| 2022-06-30 | $27.51K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-15 | $62.37K 6-K · filed 2023-08-15 | ||
| 2022-03-31 | $34.86K 6-K · filed 2023-05-16 | |||
| 2021-12-31 | $69.93K 20-F · filed 2024-04-09 | |||
| 2021-06-30 | $34.84K 6-K · filed 2022-09-07 | |||
| 2020-12-31 | $60.46K 20-F · filed 2023-04-07 | |||
| 2019-12-31 | $53.04K 20-F · filed 2022-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |